Sino Biopharmaceutical (HK:1177) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sino Biopharmaceutical is set to acquire a 29.99% equity interest in Hob Biotech Group, with a potential additional offer for 25.01%. The agreement includes profit undertakings for Hob Biotech, ensuring net profits of at least RMB49.70 million in 2024, with cash compensation required if targets aren’t met. This acquisition highlights Sino Biopharmaceutical’s strategic investment in the biotech sector, offering potential growth opportunities for investors.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.